EUVIMEDEUVIMED entdecken
Crossref

TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC

Shiwei Liu, Zhe Hong, Zhongyuan Wang, Yongqing Zhang, Chenye Jiang, Yuchen Jiang, Runkai Zhang, Zheng Liu, Zhi Shang, Guowen Lin, Zongyuan Hong, Bo Dai

Science Advances · 20.11.2026 · 12 (47)

DOI: 10.1126/sciadv.aec9042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 20.11.2026. Verfasst von Shiwei Liu und 11 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both intrinsic and acquired resistance to poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as a formidable challenge in clinical practice. Here, we report that the transcription factor E-twenty-six (Ets)-related gene ( ERG ) was highly expressed in PARPi-resistant prostate cancer and was correlated with PARPi resistance in castration-resistant prostate cancer (CRPC) cells. ERG was posttranslationally modified by tripartite motif-containing 28 (TRIM28) as SUMOylation at lysine 389 (K389), which promotes DNA homologous recombination repair (HRR), thereby weakening the efficacy of PARPis. Mechanistically, the SUMOylation of ERG (K389) inhibited protein degradation mediated by the SPOP-mediated ubiquitin-proteasome pathway, thereby stabilizing the protein. Concurrently, this posttranslational modification increased HRR capacity by inhibiting 53BP1 expression, which in turn reduced PARPi sensitivity. Blockade of ERG K389 SUMOylation can effectively impair DNA repair efficacy and overcome PARPi resistance. These findings suggest that TRIM28-mediated ERG SUMOylation conveys resistance to PARPis by inhibiting 53BP1 expression; combined TRIM28/ERG targeting and PARPi therapy may improve outcomes for ERG-positive CRPC patients.

Zitieren

APA

Liu, S., Hong, Z., Wang, Z., Zhang, Y., Jiang, C., Jiang, Y., Zhang, R., Liu, Z., Shang, Z., Lin, G., Hong, Z., & Dai, B. (2026). TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC. Science Advances, 12(47). https://doi.org/10.1126/sciadv.aec9042

Vancouver

Liu S, Hong Z, Wang Z, Zhang Y, Jiang C, Jiang Y, et al. TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC. Science Advances. 2026;12(47). doi:10.1126/sciadv.aec9042

BibTeX
@article{Liu2026,
  author = {Liu, Shiwei and Hong, Zhe and Wang, Zhongyuan and Zhang, Yongqing and Jiang, Chenye and Jiang, Yuchen and Zhang, Runkai and Liu, Zheng and Shang, Zhi and Lin, Guowen and Hong, Zongyuan and Dai, Bo},
  title = {TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {47},
  doi = {10.1126/sciadv.aec9042}
}
Kostenlos starten →